Author | Thomas G. Martin, MD


Peripheral Neuropathy Experience in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Carfilzomib

December 02, 2013

ByThomas G. Martin, MD

The adverse event profile of single-agent carfilzomib suggests that the agent is an important treatment option for patients with advanced multiple myeloma, particularly those with pre-existing peripheral neuropathy or those who are at risk for the development of peripheral neuropathy.